Hematology / Oncology CE Activities

Hematology / oncology blog

View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

RMEI Presentations


View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.


RSS Latest Hematology / Oncology Articles
  • Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes September 28, 2023
    In patients with atrial high-rate episodes, edoxaban did not significantly reduce the incidence of stroke and cardiovascular outcomes as compared with placebo, but it led to a higher incidence of bleeding.
    Paulus Kirchhof, Tobias Toennis, Andreas Goette, A. John Camm, Hans Christoph Diener, Nina Becher, Emanuele Bertaglia, Carina Blomstrom Lundqvist, Martin Borlich, Axel Brandes, Nuno Cabanelas, Melanie Calvert, Gregory Chlouverakis, Gheorghe-Andrei Dan, Joris R. de Groot, Wolfgang Dichtl, Borys Kravchuk, Andrzej Lubiński, Eloi Marijon, Béla Merkely, Lluís Mont, Ann-Kathrin Ozga, Kim Rajappan, Andrea Sarkozy, Daniel Scherr, Rafał Sznajder, Vasil Velchev, Dan Wichterle, Susanne Sehner, Emmanuel Simantirakis, Gregory Y.H. Lip, Panos Vardas, Ulrich Schotten, Antonia Zapf, the NOAH-AFNET 6 Investigators
  • Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations September 21, 2023
    The use of dabrafenib plus trametinib in pediatric low-grade glioma with BRAF V600 mutations led to longer progression-free survival and fewer grade 3 adverse events than standard chemotherapy.
    Eric Bouffet, Jordan R. Hansford, Maria Luisa Garrè, Junichi Hara, Ashley Plant-Fox, Isabelle Aerts, Franco Locatelli, Jasper van der Lugt, Ludmila Papusha, Felix Sahm, Uri Tabori, Kenneth J. Cohen, Roger J. Packer, Olaf Witt, Larissa Sandalic, Ana Bento Pereira da Silva, Mark Russo, Darren R. Hargrave
  • A Holy Grail — The Prediction of Protein Structure September 21, 2023
    The 2023 Lasker Award for Basic Medical Research underscores the value of an AI system that predicts the three-dimensional structure of proteins from the one-dimensional sequence of their amino acids.
    Russ B. Altman


View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.